Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
Authors: Jones, R., Casbard, A., Carucci, M., Smith, J., Ingarfield, K., Gee, J.M.W., Hudson, Z., Alchami, F., Hayward, L., Hickish, T., Hwang, D., McAdam, K., Spensley, S., Waters, S., Wheatley, D., Beresford, M.
Journal: ANNALS OF ONCOLOGY
Publication Date: 09/2020
Volume: 31
Pages: S1151
eISSN: 1569-8041
ISSN: 0923-7534
DOI: 10.1016/j.annonc.2020.08.2248
Source: Web of Science